Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

The_Blue_Print Mar. 15 at 5:57 PM

$RVMD big increase coming

0 · Reply

MarketMaestro1 Mar. 14 at 4:19 PM

I know in my heart I need to be much bigger long $VKTX, and I already am pretty bigly long. This company below is trading at a P/E of 10! 10!!!! The biggest rocket ship of all time is taking off, and the next-gen version that for some reason dumbass $LLY didn’t make is trading for $4 billion. What the hell is happening in markets? $VKTX should probably be nearer $RVMD valuation. I know it sounds insane but what is oral tirzepatide worth!? And $NVO is trading like oral Wegovy is not going to do double digit billions next year (it definitely is).

1 · Reply

Biotech_Pharma_Investor Mar. 14 at 1:02 PM

$RVMD ?

0 · Reply

SuperGreenToday Mar. 13 at 9:57 PM

$RVMD Share Price: $94.85 Contract Selected: Jun 18, 2026 $95 Calls Buy Zone: $12.32 – $15.23 Target Zone: $20.21 – $24.70 Potential Upside: 55% ROI Time to Expiration: 96 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

truehealthvalue Mar. 12 at 8:39 PM

$RVMD take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

biolover Mar. 12 at 6:15 PM

$TNGX nothing in the whole us market with stronger technicals than TNGX. Drug works. BIC. Partnership with $RVMD , tons of strong long instructions that joined from q2-q4 and massive SI that has to cover. The technical pressure up is even more intense than strong fundamentals.

0 · Reply

watchaddict Mar. 11 at 2:17 PM

$RVMD adding

0 · Reply

Alt_Fuel Mar. 11 at 10:48 AM

$VSTM $ERAS Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - March 10, 2026 “We are encouraged by the early clinical activity observed for ERAS-0015 across multiple tumor types and RAS mutations at a fraction of the dose seen for RMC-6236. [ RMC-6236 is produced by $RVMD ] We believe that the clinical data generated to date, including what we have observed from a substantial number of patients treated in China, underscore the potential differentiation and benefit of ERAS-0015 for patients with RAS-mutant cancers globally,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Exercising this option to expand our license agreement and secure worldwide rights reflects our strong conviction in ERAS-0015’s potential, and we look forward to collaborating with the Chinese investigators to continue developing ERAS-0015 for patients in China and globally.” https://investors.erasca.com/news-releases/news-release-details/erasca-exercises-option-secure-worldwide-rights-eras-0015-pan

0 · Reply

PMMstocks Mar. 11 at 9:00 AM

$ELTX $RVMD $MRK https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-elicio-therapeutics-stock-with-buy-rating-93CH-4550688

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

$VSTM Specific details on exact conferences and presentation dates for updated GFH375 (VS-7375) data in 2026 have not yet been publicly announced by GenFleet Therapeutics or its partner Verastem Oncology... $ANL ... $ERAS ... $RVMD However, Verastem has outlined plans to report an interim safety and efficacy update from the ongoing U.S.-based Phase 1/2 trial (VS-7375-101) in the first half of 2026, with a more comprehensive update in the second half of 2026. These timelines could align with major oncology conferences, such as: AACR Annual Meeting: April 17-22, 2026 (San Diego, CA). ASCO Annual Meeting: May 29-June 2, 2026 (Chicago, IL). Other global oncology events later in 2026 where data might be presented include ESMO Congress ( September ?) or the World Conference on Lung Cancer ( September ?)... GenFleet - intends to share updates across indications like NSCLC, PDAC, and other KRAS G12D-mutant solid tumors at international events throughout 2026 - no specific dates confirmed...

0 · Reply

Harbor Health Care ETF Q4 2025 Portfolio Review

ABBV ABVX GMAB LLY MASI MEDI MRK

Mar 3, 2026, 11:52 AM EST - 12 days ago

Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 25, 2026, 9:17 PM EST - 18 days ago

Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 4:02 PM EST - 18 days ago

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb 24, 2026, 4:05 PM EST - 19 days ago

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:05 PM EST - 25 days ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb 11, 2026, 10:54 AM EST - 4 weeks ago

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 4, 2026, 4:05 PM EST - 5 weeks ago

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 29, 2026, 10:30 PM EST - 6 weeks ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GKOS GMAB

Jan 26, 2026, 4:30 PM EST - 6 weeks ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK

Jan 26, 2026, 6:01 AM EST - 7 weeks ago

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

MRK

Jan 25, 2026, 3:27 PM EST - 7 weeks ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

MRK

Jan 25, 2026, 2:30 PM EST - 7 weeks ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK

Jan 12, 2026, 5:26 PM EST - 2 months ago

Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 9, 2026, 2:58 PM EST - 2 months ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

MRK

Jan 9, 2026, 2:33 PM EST - 2 months ago

Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle

Jan 9, 2026, 5:54 AM EST - 2 months ago

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.

Jan 8, 2026, 3:56 PM EST - 2 months ago

Merck in talks to buy biotech Revolution Medicines, FT reports

MRK

Jan 8, 2026, 8:00 AM EST - 2 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Jan 8, 2026, 7:38 AM EST - 2 months ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

ABBV

Jan 7, 2026, 2:58 PM EST - 2 months ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

ABBV

Jan 7, 2026, 2:48 PM EST - 2 months ago

AbbVie Near Deal for Revolution Medicines

ABBV

Jan 5, 2026, 4:05 PM EST - 2 months ago

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 18, 2025, 11:48 AM EST - 4 months ago

Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 10:51 AM EST - 4 months ago

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 5, 2025, 8:41 PM EST - 4 months ago

Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:02 PM EST - 4 months ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 4, 2025, 4:05 PM EST - 4 months ago

Revolution Medicines to Participate in November 2025 Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Oct 22, 2025, 12:12 PM EDT - 5 months ago

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Oct 16, 2025, 8:00 PM EDT - 5 months ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Sep 29, 2025, 9:00 AM EDT - 6 months ago

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Sep 11, 2025, 2:14 PM EDT - 6 months ago

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Sep 11, 2025, 1:30 PM EDT - 6 months ago

Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold

Sep 11, 2025, 8:44 AM EDT - 6 months ago

Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript)

Sep 10, 2025, 4:02 PM EDT - 6 months ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Aug 7, 2025, 5:49 AM EDT - 7 months ago

Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:02 PM EDT - 7 months ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Jul 24, 2025, 4:00 PM EDT - 8 months ago

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Jul 23, 2025, 8:00 AM EDT - 8 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

SMMT

Jun 24, 2025, 7:19 AM EDT - 9 months ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

RPRX

Jun 24, 2025, 7:00 AM EDT - 9 months ago

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Jun 23, 2025, 9:00 AM EDT - 9 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Jun 19, 2025, 11:54 AM EDT - 9 months ago

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

May 14, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

The_Blue_Print Mar. 15 at 5:57 PM

$RVMD big increase coming

0 · Reply

MarketMaestro1 Mar. 14 at 4:19 PM

1 · Reply

Biotech_Pharma_Investor Mar. 14 at 1:02 PM

$RVMD ?

0 · Reply

SuperGreenToday Mar. 13 at 9:57 PM

0 · Reply

truehealthvalue Mar. 12 at 8:39 PM

0 · Reply

biolover Mar. 12 at 6:15 PM

0 · Reply

watchaddict Mar. 11 at 2:17 PM

$RVMD adding

0 · Reply

Alt_Fuel Mar. 11 at 10:48 AM

0 · Reply

PMMstocks Mar. 11 at 9:00 AM

$ELTX $RVMD $MRK https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-elicio-therapeutics-stock-with-buy-rating-93CH-4550688

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

0 · Reply

Quantumup Mar. 9 at 1:58 PM

Truist reiterated $IDYA Buy/$60 $RVMD $TNGX IMRX $BMY $AMGN Here's what Truist said in its note: https://x.com/Quantumup1/status/2031005706770350568?s=20

0 · Reply

biolover Mar. 9 at 1:26 AM

$VKTX will be fine tomorrow. This few share psychological shorting is meaningless. Friday and recent action was reminiscent of $RVMD move prior to $MRK interest leak. Even spotted at CNBC. As much as VK CEO is tight lipped, Abbv , $NVO or others interest is very real and negotiation news often leak.

1 · Reply

Quantumup Mar. 6 at 2:27 PM

Clear Street⬆️ $ERAS's PT to $20 from $11 and reiterated at a Buy rating. $TNGX $IMRX $RVMD $BBOT Erasca announced a clinical trial and supply agreement (CTCSA) with Tango Therapeutics (TNGX, NC) to evaluate ERAS-0015 in combination with Tango's PRMT5 inhibitor, vopimetostat (TNG462). We view this as a capital-efficient initiative that increases ERAS-0015's combination flexibility and brings an MTAPdel RASm approach. We raise our PT to $20 (from $11) based on (1) higher PoS for ERAS-0015—55% in PDAC, 40% in NSCLC (up from 30% each), reflecting notable MTAP deficiency prevalence (35% for PDAC, 15% for NSCLC per Tango) and confidence in an additional combination strategy, and (2) a reduced discount rate to 12% (from 13%) on increased external validation.

0 · Reply

Alt_Fuel Mar. 5 at 7:21 PM

$VSTM Jefferies reiterates Verastem $VSTM stock rating on launch progress - 03/05/2026, 10:54 AM https://www.investing.com/news/analyst-ratings/jefferies-reiterates-verastem-stock-rating-on-launch-progress-93CH-4544702 Next 6 to 12 months will be interesting ... $ERAS $ANL $RVMD

0 · Reply

PMMstocks Mar. 4 at 4:47 PM

$ELTX $RVMD $SPY $QQQ $MRNA Elicio to go in 1 hour at TD Cowen. Big expectations on update for FDA Phase 3 advances.

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 3:54 PM

$CAPR $RVMD $SLS $SMMT I expect 1st Sellas trading T1 halt over $7.09+ ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 3:12 PM

$CAPR $RVMD $SLS $SMMT Good Dr. Angelos Stergiou Overwhelming Paradigm shifting Linkedln posts have stopped in preparation of the Binary Catalyst PR. Sellas BOD has 2 business days to PR after accepting a written offer. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 2:31 PM

$CAPR $RVMD $SLS $SMMT SLS 1st trading halt at $7.09. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 1:08 PM

$CAPR $RVMD $SLS $SMMT Keep an eye out for SLS Nasdaq T1 Halt Schedule. 1st open after halt $60.00- $120.00+ 🙏☝️✌️❤️‍🩹

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 12:23 PM

$RVMD $SLS $SMMT $CAPR I wanted to Thank again CAPR Shareholder that sold me CAPR shares Pre market on 12/3/25 👇 at $4.25 half an hour before the halt. I resold those shares after the halt was lifted at $40.22. I put the sell order at SELL @38.77 LMT but it opened at $40.22 . Now that's how Binary Catalyst Stocks work. GPS Regal Pivotal Registrational phase 3 results will shake up the entire Oncology/Hematology sector and BO shortly thereafter = $120.00+👇 ✌️❤️‍🩹👏

0 · Reply

SellasgpsCurativeBAT9 Mar. 4 at 12:04 PM

$RVMD $SLS $SMMT My Long Brothers and Sisters follow the following trading halt schedule in the coming hours and days: 1st trading halt $60.00- $100.00+ 2nd Trading Halt= $100- $150.00+ 3rd Trading Halt= $180.00- $220.00+ See you all on the other side. ✌️🙏❤️‍🩹👏

1 · Reply

SellasgpsCurativeBAT9 Mar. 3 at 8:18 PM

$RVMD $SLS $SMMT SLS Repositioners, Traders and Shorts can buy at $60.00+ after 1st Halt. ✌️🙏❤️‍🩹👌

1 · Reply

Market Cap	18.80B
Revenue (ttm)	0.00
Net Income (ttm)	-1.13B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	1,465,600
Avg Vol	3,580,730
Day's Range	N/A - N/A
Shares Out	198.17M
Stochastic %K	2%
Beta	0.99
Analysts	Strong Sell
Price Target	$128.33